11
Apr
2022
Category: Blog
28
Mar
2022
Bionest
ASH 2021 Update: Part 2
A look at new hematology therapy developments for hemophilia, beta thalassemia and sickle cell disease presented at ASH 2021.
14
Mar
2022
Bionest
ASH 2021 Update: Part One
Are anti-CD38 antibodies & CAR-T treatments living up to their promise for multiple myeloma patients? We examine clinical trial results shared at ASH2021
28
Feb
2022
Bionest
Trends to Watch in 2022 after the 40th Annual JPM Conference
Fewer blockbuster M&A announcements, more early-stage partnerships & acquisitions. We examine trends for 2022 that emerged at JPM
14
Feb
2022
Bionest
AI Analysis of Real-World Data to Improve Rare Disease Diagnosis
Could artificial intelligence (AI) be harnessed to help diagnose rare diseases? We explore the technology & how it is being used in Fabry disease.
31
Jan
2022
Bionest
What’s Next for mRNA?
Beyond COVID and cancer: In which indications will we see mRNA technology succeed next? And what technological advances might next-generation mRNA platforms offer over those used in the COVID-19 vaccines?
17
Jan
2022
Bionest
Novartis and UK NHS Collaborate for Targeted Access to Levqio
Novartis is teaming up with the NHS to make the PCSK9 inhibitor Leqvio available for UK heart patients who struggle to control their LDL cholesterol with existing drugs.
27
Dec
2021
Bionest
Addressing Gene Therapy UncertaintiesÂ
Are we close to more streamlined and standardized approaches to gene therapy testing and regulations?
13
Dec
2021
Bionest
UK Policy Changes Allow Earlier Access to Innovative Medicines for Rare Diseases
Access to new treatments for rare diseases in the UK has often been a challenge. Will a new decision-making framework & funding improve the situation?
30
Nov
2021